Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2014)
24 slides from Invion's shareholder meeting presentation, Nov 21, 2014
Slide 1: Invion Limited Investor Presentation to AGM
For personal use only Invion Limited (ASX:IVX) Clinical-stage life sciences company targeting chronic inflammation Investor Presentation to AGM 21 November | 2014
Slide 2: Invion: targeting inflammation
Invion: targeting inflammation For personal use only > Global life sciences group in pharmaceutical drug development > Expertise and assets target chronic inflammation in two key areas of human health: > inflammatory airways disease (respiratory disease) > inflammation caused by autoimmune disease >
Slide 3: Invion's assets
Invion’s assets For personal use only Respiratory > INV102 (nadolol): a beta blocker (beta adrenergic biased ligand) currently used to treat high blood pressure, coronary chest pain (angina) and migraine, is being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). > INV
Slide 4: Strategic goals
Strategic goals For personal use only 1. Gain US FDA approval for INV102 (nadolol) as a treatment for cigarette smokers who repeatedly fail to quit 2. Demonstrate proof of concept for inhaled INV102 (nadolol) in the treatment of one or more diseases of the airway including severe asthma, COPD and cy
Slide 5: Pipeline
Pipeline For personal use only Formulation ………….. ………….. ………….. Research Phase I Phase II development and clinical feasibility Next milestone Oral INV102 (nadolol) Reporting Asthma NIH funded 2H15 Completion, final data Smoking cessation & reporting 1H15 Inhaled INV102 (nadolol) Asthma Pre-IND meeti
Slide 6: Targeting chronic inflammatory airway disease
For personal use only Targeting chronic inflammatory airway disease INV102 (nadolol) INV104 (zafirlukast)
Slide 7: Spectrum of airway disease and opportunities
Spectrum of airway disease and opportunities For personal use only Global market size: $34B $2.4B $1.2B Exercise Mild Moderate Severe Chronic Smoker’s Cystic Induced Asthma Asthma Asthma Bronchitis Cough Fibrosis Asthma INV104 (zafirlukast) INV102 (nadolol) Monotherapy + combinations Monotherapy + c
Slide 8: The critical role of the epithelium in severe airway disease
The critical role of the epithelium in severe airway disease Normal respiratory epithelium Severe asthma For personal use only Chronic bronchitis Cystic fibrosis 8
Slide 9: INV102 reverses epithelial changes in pre-clinical studies
INV102 reverses epithelial changes in pre-clinical studies For personal use only Control lung tissue Lung tissue of ‘asthmatic’ mice: epithelial Lung tissue of ‘asthmatic’ mice treated cells have been converted to mucus- with INV102 (nadolol) for 28 days: producing goblet cells. No effect of restore
Slide 10: INV102 reverses epithelial changes via inhibition of the beta-arrestin pathway
INV102 reverses epithelial changes via inhibition of the beta-arrestin pathway For personal use only > INV102 development is based on the science of Richard A. Bond PhD, Professor of Pharmacology, U Houston. In collaboration with nobel-prize winning Robert Lefkowitz, Dr Bond undertook studies on the
Slide 11: Respiratory therapeutics: oral program
For personal use only Respiratory therapeutics: oral program INV102 (nadolol)
Slide 12: Oral INV102: emerging phase II clinical data
Oral INV102: emerging phase II clinical data For personal use only Phase II asthma trial (NIMA): interim analysis > Randomised, placebo-controlled, 60 patient clinical trial in patients with mild asthma > High % of patients (> 90%) tolerated titration to maximum possible dose without severe adverse
Slide 13: Respiratory therapeutics: inhaled program
For personal use only Respiratory therapeutics: inhaled program INV102 (nadolol) in asthma, COPD & cystic fibrosis INV104 (zafirlukast) in asthma
Slide 14: Inhaled INV102: program status
Inhaled INV102: program status For personal use only > Collaboration with 3M Drug Delivery systems > Target outcome: proprietary formulation and device using 3M’s proprietary pressurised metered dose inhalation (pMDI) technology > Collaboration encompasses manufacture for toxicology and phase I stud
Slide 15: Inhaled INV104: program status
Inhaled INV104: program status For personal use only > First inhaled non-steroidal anti-inflammatory drug for asthma > Ongoing collaboration to develop proprietary formulation and device > Largely risk mitigated development based on chemistry, inhaled toxicology and inhaled proof of concept studies
Slide 16: Respiratory Pipeline
Respiratory Pipeline For personal use only Formulation ………….. ………….. ………….. Research Phase I Phase II development and clinical feasibility Next milestone Oral INV102 (nadolol) Reporting Asthma NIH funded 2H15 Completion, final data Smoking cessation & reporting 1H15 Inhaled INV102 (nadolol) Pre-IND
Slide 17: Targeting chronic inflammation caused by autoimmune disease
For personal use only Targeting chronic inflammation caused by autoimmune disease INV103 (ala-Cpn10)
Slide 18: INV103 (ala-Cpn10): background and rationale
INV103 (ala-Cpn10): background and rationale For personal use only > Modified naturally occurring protein > Intracellular function: prevent protein misfolding > Extracellular function: proposed as founding member of the Resolution Associated Molecular Cpn10 Pattern (RAMPs) family - a critical compon
Slide 19: INV103 phase II lupus trial: interim blinded data
INV103 phase II lupus trial: interim blinded data For personal use only > Double-blind, randomised, placebo-controlled clinical trial in lupus patients. Up to 40 subjects in up to 5 cohorts (8 patients per cohort), increasing dose and increasing disease severity. Doses 10mg, 30mg, 100mg, 300mg > Dat
Slide 20: Invion: key milestones next 12-18 months
Invion: key milestones next 12-18 months For personal use only 2H 2014 Interim data from NIH-funded phase II study of INV102 (nadolol) in asthma patients Interim data from phase II study of INV103 (ala-Cpn10) in lupus patients > Phase II interim data from oral INV102 (nadolol) study in patients
Slide 21: Summary
For personal use only Summary 3 drug assets with multiple paths to market 3 FDA-regulated phase II clinical trials early partnering opportunity for INV103 (ala-Cpn10) two de-risked novel and proprietary inhaled respiratory assets collaboration with global partner on inhaled franchise exp
Slide 22: Corporate snapshot
Corporate snapshot For personal use only Sector Life Sciences (Biotechnology) Principal activities Clinical-stage pharmaceutical drug development Pipeline 3 drug assets, multiple clinical and pre-clinical programs Operations Australia & USA ASX code IVX Share price (31-Oct-14) $0.053 (5.3 cents) Sha
Slide 23: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Invion Limited (Invion or the Company) solely for its use at presentations to be made by the Company. The information contained in this presentation is an overview and does not contain all information necessary to make investmen
Slide 24: Dr Greg Collier, Managing Director and CEO
For personal use only Dr Greg Collier Managing Director and CEO Invion Limited GPO Box 1557 Brisbane, QLD, 4001 Australia P: +61 7 3295 0500 E: greg.collier@inviongroup.com W: www.inviongroup.com Investor Presentation November | 2014